N/A N=7,604 Comfort Talk and Economic Outcomes in MRI
Claustrophobia · Complication of Diagnostic Procedure
Primary: Equipment Utilization Q4FY15 = Baseline Quarter (OSU) — 0.83; 0.77 Proportion of completed scans per slots
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=69 A Study to Look at Tapentadol Tablets in Children and Adolescents in Pain
Pain
Primary: Number of Participants Classified as Responder (Part 1) — 19; 32 Participants — p=0.0790
Phase 3 N=71 A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory PTCL
Refractory Peripheral T-Cell Lymphoma · Relapsed T-Cell Lymphoma
Primary: Objective Response Rate(ORR) by International Working Group Criteria — 37 Participants
N/A N=10 Single Hormone Closed Loop Study With PDT Sensor
Type 1 Diabetes Mellitus
Primary: Mean Absolute Relative Difference of Sensed Glucose Values — 13.5 percentage of reference blood glucose
Phase 2 N=46 TKI258 in Castrate Resistant Prostate Cancer
Prostate Cancer
Primary: The Number of Participants With Improvement, Disease Progression or Stable Disease — 6; 4; 13 Participants
N/A N=99 Imaging the Effects of Stimulant Medication on Emotional Lability in Patients With ADHD
Attention Deficit Hyperactivity Disorder
Primary: Brain Structure Volume — 3909.85; 4069.72; 1431.31; 1485.05 mm^3
Phase 3 N=2,250 Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants
Pneumonia, Pneumococcal
Primary: Serotype-specific Geometric Mean Concentration of IgG Antibody — 4.08; 4.24; 4.58; 1.34 µg/mL
Phase 4 N=80 Recovery and Analgesia After Surgery for Gynecological Cancer
Gynecological Cancer
Primary: Length of Stay — 4.3; 3.3 days
N/A N=200 Validation of the Freund Clock Drawing Test to Screen for Cognitive Dysfunction in Cancer Patients
Elderly Cancer Patients · Cognitive Impairment
Primary: Validation of the Freund Clock Drawing Test, and Its Predefined Cut-off of ≤ 4, as a Screening Tool to Identify Elderly Cancer Patients in Need of a More In-depth…
Phase 2 N=55 PREMIX vs PREMED Intranasal Lidocaine and Midazolam
Pain
Primary: Procedural Distress, OSBD-R — 6.4; 7 Units on a scale
Phase 3 N=95 Dosing Validation Study of Oral Testosterone Undecanoate (TU, LPCN 1021).
Hypogonadism, Male
Primary: Percent of LPCN 1021-treated Subjects Who Achieve a Total Testosterone Average Concentration [Cavg] in the Normal Range — 80 Percent of participants
N/A N=82 Shunt Tube Exposure Prevention Study
Glaucoma
Primary: Number of Participants With Tube Erosion — 2; 11 Participants
Phase 3 N=330 A Study of Vilazodone in Pediatric Patients With Major Depressive Disorder
Major Depressive Disorder
Primary: Number of Participants to Experience a Treatment Emergent Adverse Event (TEAE) — 90; 89; 48; 10 Participants
N/A N=705 Women's Improvement of Sexual Health (WISH) Demonstration Project
Sexually Transmitted Disease · Bacterial Vaginosis · Vaginal Candidiasis
Primary: Feasibility of Integrating Point-of-care Testing (Monitoring & Evaluation Indicators) — 396; 378; 399; 216 Participants
Phase 3 N=100 Dosing Flexibility Study of Oral Testosterone Undecanoate (TU, LPCN 1021)
Hypogonadism, Male
Primary: Percent of LPCN 1021-treated Subjects Who Achieve a Total Testosterone Average Concentration [Cavg] in the Normal Range — 69 Percent of participants